Il lancio degli YELLOW WEBINARS aggiunge un’importante attività al ruolo multitasking la Fondazione Italiana Fegato. Poiché la pandemia del 2020 ha cambiato sostanzialmente le nostre vite, abbiamo deciso di trasformare i tradizionali Yellow Seminars in presenza in Yellow Webinars consentendo alla FIF di diffondere meglio e ampiamente il messaggio scientifico . La qualità dei relatori e la rilevanza degli argomenti sono autoesplicativi.
Gli Yellow Webinars si svolgono sulla nostra piattaforma Zoom
_____________
The launch of the YELLOW WEBINARS adds an important activity to the multitasking role of the Italian Liver Foundation. Since the 2020 pandemic has substantially changed our lives, we have decided to transform the traditional Yellow Seminars in presence into Yellow Webinars allowing the FIF to better and widely disseminate the scientific message. The quality of the speakers and the relevance of the topics are self-explanatory.
The Yellow Webinars are hosted on our Zoom platform
Zoom ID : 454 870 8300
pw: liver
Download – YW Calendar 2026
Watch the past Yellow Webinars on
FIF Youtube Channel
https://www.youtube.com/@fondazioneitalianafegato
JANUARY 12
The Nectin Family of Proteins:
Emerging Targets in Hepatocellular Carcinoma
Paola Kucan Brlic
Associate Professor, Center for Proteomics
Faculty of Medicine, University of Rijeka, Croatia
JANUARY 26
Multimodal decoding of human liver regeneration and repair
Neil Henderson
Professor of Tissue Repair and Regeneration
Wellcome Trust Senior Research, Fellow in Clinical Science – Co-Director, Wellcome Trust
Edinburgh Clinical Academic Track (ECAT) Programme Centre for Inflammation Research, Institute for
Regeneration and Repair, University of Edinburgh, UK
FEBRUARY 23
Human Endogenous Retroviruses (HERVs) in Inflammatory Liver Disease: something to consider or nothing doing?
Udeme Ekong,
MD MPH FAASLD
Professor of Pediatrics and Surgery,
Georgetown University School of Medicine
Attending Physician, Pediatric Hepatology and Transplant Hepatology
Medstar Georgetown Transplant Institute
National Board of Directors, American Liver Foundation
MARCH 9
Immunogenomics and chemotherapy resistance in biliary tract cancers
Jesper Andersen.
JM.Sc., Ph.D.
Professor of Translational Hepatology
Head of Andersen group
Biotech Research and Innovation Centre (BRIC)
Dept. of Health and Medical Sciences
University of Copenhagen, Denmark
MARCH 23
Micro- & Nanoplastic Pollution
and Liver Disease:
An Emerging Health Concern
Shilpa Chokshi
PhD, FRSB,
Director, Centre of Environmental Hepatology
Professor of Experimental Hepatology,
University of Plymouth, UK
APRIL 13
Therapies for Liver Cirrhosis
Using Allogeneic Mesenchymal Stromal Cells and the Development of Extracellular Vesicle–Based Treatments
Shuji Terai
Professor and Chairman,
Division of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Niigata University
Vice President, The Japanese Society for Regenerative
Medicine JSRM Auditor JSGE. Director JSH
APRIL 27
Treatment of liver cancer with impaired hepatic function
Stephen Chan
MBBS (HK), MD (CUHK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond)
The Chinese University of Hong Kong
MAY 4
Phosphatidylethanol
in steatotic liver disease
Nikolaj Torp
Centre for Liver Research,
Department of Gastroenterology & Hepatology, Odense University Hospital
Clinical Institute, Department of Health
Sciences, University of Southern Denmark
MAY 18
Mitochondrial Plasticity in Steatotic Liver Disease: from Adaptive Dynamics to Organelle Pathology
Elena Palma
Principal Investigator & Lecturer (adj.)
Roger Williams Institute of Liver Studies
King’s College London, UK
JUNE 8
The Immune Renaissance in Hepatocellular Carcinoma: Immunotherapy Mechanisms, Breakthroughs, and the Road Ahead
Francesco Tovoli
MD, PhD
Department of Medical and Surgical
Sciences, University of Bologna, Italy
JUNE 22
Reimagining the use of immunotherapy in early-stage HCC
Antonio D’Alessio
MD, PhD, Consultant Medical Oncologist
Honorary Senior Clinical Lecturer
Guy’s and St.Thomas’s NHS Foundation Trust
Kings College Hospital
NHS Foundation Trust
JULY 7
Impact of MASH on tumor immune interactions during HCC development
Anthony Lozano
Associate scientist
Department of Liver Diseases
Department of Immunology and Immunotherapy
Icahn School of Medicine at Mount Sinai